ISRCTN66370377 https://doi.org/10.1186/ISRCTN66370377

Can we reduce the environmental impact of nitrous oxide anaesthesia without affecting patient care?

Submission date
24/10/2024

Recruitment status
Recruiting

Registration date
27/02/2025

Overall study status
Ongoing

Last Edited
21/02/2025

Condition category
Surgery

[X] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[_] Results
[_] Individual participant data
[X] Record updated in last year

Plain English summary of protocol

Background and study aims
Nitrous oxide is a gas used in anaesthesia. The way it is currently used leads to waste and may have an environmental impact too. The way nitrous oxide is delivered is changing in operating theatres. Currently, most hospitals use piped nitrous oxide, whereas in future nitrous oxide may come from a portable cylinder instead. The aim of this study is to check whether nitrous oxide from portable cylinders is as safe for patients and less wasteful than piped nitrous oxide.

Who can participate?
All patients undergoing surgery under general anaesthetic

What does the study involve?
Patients requiring nitrous oxide anaesthesia during their operation will be randomly allocated to receive it either via cylinder or pipeline. No trial-specific data will be collected from the patient, the collection of outcome data will be via hospital record review.

What are the possible benefits and risks of participating?
There will be no direct benefits to individual patients. The intervention (nitrous oxide delivered via cylinder) is in common clinical practice in the UK, therefore there are no specific risks relating to participation in the trial, however, the purpose of the study is to assess whether there is any difference in the safety profile of nitrous oxide delivered via cylinder or via pipeline.

Where is the study run from?
The University of Birmingham (UK)

When is the study starting and how long is it expected to run for?
February 2024 to October 2025

Who is funding the study?
The National Institute for Health and Care Research (UK)

Who is the main contact?
Prof. Rupert Pearse, NOBLE@trials.bham.ac.uk

Contact information

Type(s)
Principal Investigator

Contact name
Mr Rupert Pearse

Contact details
Adult Critical Care Unit
Royal London Hospital
Whitechapel
London
United Kingdom
E1 1FR
+44 (0)20 3594 0351
r.pearse@qmul.ac.uk

Type(s)
Public

Contact name
Ms Rachel Lillywhite

Contact details
Birmingham Clinical Trials Unit
Public Health Building
University of Birmingham
Birmingham
United Kingdom
B15 2TT
+44 (0)7514800721
noble@trials.bham.ac.uk

Type(s)
Scientific

Contact name
Mr Bryar Kadir

Contact details
Birmingham Clinical Trials Unit
Public Health Building
University of Birmingham
Birmingham
United Kingdom
B15 2TT

+44 (0)7514800721
noble@trials.bham.ac.uk

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number
347203

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
RG_24-084

Study information

Scientific Title
A multi-centre non-inferiority cluster trial comparing outcomes related to nitrous oxide delivery by portable cylinder and pipeline in all patients undergoing surgery under general anaesthesia: Nitrous Oxide management to Balance heaLthcare and Environmental needs (NOBLE)

Acronym
NOBLE

Study objectives
Nitrous oxide delivered via portable cylinder is as safe in terms of patient outcomes as nitrous oxide delivered via pipeline manifold.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 20/02/2025, East of England - Cambridge Central Research Ethics Committee (2 Redman Place , London , E20 1JQ, United Kingdom; +44 (0)207 104 8089; cambridgecentral.rec@hra.nhs.uk), ref: 24/EE/0268

Study design
Pragmatic multi-centre non-inferiority cluster randomized cross-over trial

Primary study design
Interventional

Secondary study design
Randomised cross over trial

Study setting(s)
Hospital

Study type(s)
Safety

Participant information sheet

Health condition(s) or problem(s) studied
Method of nitrous oxide delivery in patients requiring surgery under general anaesthetic.

Interventions
The NOBLE trial will have two distinct phases each lasting 5 weeks. Hospitals will be randomised 1:1 either to a control phase (pipeline nitrous oxide supply) followed by an intervention phase (cylinder nitrous oxide supply), or to an intervention phase followed by a control phase. The total trial intervention period will last 10 weeks, with a further 30 days to complete the follow-up of the last included patient to undergo surgery. Hospitals will be allocated in randomised blocks of random length (4 or 6). The allocation list will be prepared by an independent statistician at BCTU, and uploaded to the randomisation module of the REDCap electronic data capture tools hosted at Birmingham University, to ensure allocation concealment when each hospital is randomised. Prior to randomisation, local investigators will ensure all necessary equipment has been procured and is ready for use and will plan the delivery of education and training to anaesthetists and relevant theatre staff.

Intervention Type
Other

Primary outcome measure
Days Alive and At Home Within 30 Days after surgery (DAH30). The day of surgery is defined as day zero. Patients who die within 30 days after surgery will be given a value of zero. DAH30 data will be collected from routine data in patient health records by local investigators who are members of the direct care team.

Secondary outcome measures
1. Use of nitrous oxide anaesthesia during surgery (Y/N)
2. Mortality within 30 days after surgery
3. Major complications during surgery (Clavien-Dindo grade ≥III)
4. Duration of hospital stay (days)
5. NHS costs of nitrous oxide provision

All secondary outcome measures will be collected from routine hospital records at 30 days after surgery

Overall study start date
01/02/2024

Completion date
31/10/2025

Eligibility

Key inclusion criteria

All patients (adults and children) undergoing surgery under general anaesthesia in participating hospitals (regardless of exposure to nitrous oxide anaesthesia)

Participant type(s)
Patient

Age group
All

Sex
Both

Target number of participants
14400

Key exclusion criteria
Patients who have opted out of anonymous data sharing
Patients undergoing repeat surgery within 30 days after a procedure recorded in the NOBLE trial

Date of first enrolment
01/04/2025

Date of final enrolment
01/10/2025

Locations

Countries of recruitment
England

Scotland

United Kingdom

Wales

Study participating centre
Barts Health NHS Trust
The Royal London Hospital
80 Newark Street
London
United Kingdom
E1 2ES

Study participating centre
Medway NHS Foundation Trust
Medway Maritime Hospital

Windmill Road
Gillingham
United Kingdom
ME7 5NY

Study participating centre
Royal Free London NHS Foundation Trust
Royal Free Hospital
Pond Street
London
United Kingdom
NW3 2QG

Study participating centre
Barking Havering & Redbridge Hospitals NHS Trust
Queens Hospital
Romford
United Kingdom
RM7 0AG

Study participating centre
United Lincolnshire Hospitals NHS Trust
Lincoln County Hospital
Greetwell Road
Lincoln
United Kingdom
LN2 5QY

Study participating centre
University Hospital Southampton NHS Foundation Trust
Southampton General Hospital
Tremona Road
Southampton
United Kingdom
SO16 6YD

Study participating centre
Norfolk and Norwich University Hospitals NHS Foundation Trust
Colney Lane
Colney
Norwich

United Kingdom
NR4 7UY

Study participating centre
Royal Surrey County Hospital NHS Foundation Trust
Egerton Road
Guildford
United Kingdom
GU2 7XX

Study participating centre
University Hospitals Plymouth NHS Trust
Derriford Hospital
Derriford Road
Derriford
Plymouth
United Kingdom
PL6 8DH

Study participating centre
Kingston Hospital NHS Foundation Trust
Galsworthy Road
Kingston upon Thames
United Kingdom
KT2 7QB

Study participating centre
Mid and South Essex NHS Foundation Trust
Nether Mayne
Basildon
United Kingdom
SS16 5NL

Study participating centre
Kings College Hospital NHS Foundation Trust
Princess Royal University Hospital
Farnborough Common
Orpington
United Kingdom
BR6 8ND

Study participating centre
County Durham and Darlington NHS Foundation Trust
Darlington Memorial Hospital
Hollyhurst Road
Darlington
United Kingdom
DL3 6HX

Study participating centre
Nottingham University Hospitals NHS Trust - Queen's Medical Centre Campus
Nottingham University Hospital
Derby Road
Nottingham
United Kingdom
NG7 2UH

Study participating centre
East Kent Hospitals University NHS Foundation Trust
Queen Elizabeth The Queen Mother Hospital Margate
Ramsgate Rd
Margate
United Kingdom
CT9 4AN

Study participating centre
East Kent Hospitals University NHS Foundation Trust
William Harvey Hospital
Kennington Rd
Willesborough
Ashford
United Kingdom
TN24 0LZ

Study participating centre
Barnet Hospital
Wellhouse Lane
Barnet
United Kingdom
EN5 3DJ

Study participating centre
Chase Farm Hospital
127 the Ridgeway
Enfield
United Kingdom
EN2 8JL

Study participating centre
Royal Cornwall Hospitals NHS Trust
Royal Cornwall Hospital
Treliske
Truro
United Kingdom
TR1 3LJ

Sponsor information

Organisation
University of Birmingham

Sponsor details
Research Governance
Research, Strategy and Services Division
Birmingham
England
United Kingdom
B15 2TT
+44 (0)7814 650003
researchgovernance@contacts.bham.ac.uk

Sponsor type
University/education

Website
http://www.birmingham.ac.uk/index.aspx

ROR
https://ror.org/03angcq70

Funder(s)

Funder type
Government

Funder Name
National Institute for Health and Care Research

Alternative Name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
The results of the trial will be submitted for publication in a peer-reviewed journal. All publications from this trial will be published under “NIHR Global Health Research Unit on Global Surgery” and/or any other collaborating author groups. Any secondary publications and presentations prepared by Investigators must be reviewed and approved by the TMG. Manuscripts must be submitted to the TMG in a timely fashion and in advance of being submitted for publication to allow time for review and resolution of any outstanding issues. Authors must acknowledge funding from the National Institute for Health and Care Research. Intellectual property rights will be addressed in the Clinical Trial Site Agreement between the Sponsor and hospital site.

Intention to publish date
31/10/2026

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study will be available upon request from Rachel Lillywhite (NOBLE@trials.bham.ac.uk)

IPD sharing plan summary
Available on request